Symbiotec Pharmalab Ltd will open its Rs 1,757 crore [4] initial public offering for subscription on Aug. 24, 2026 [5].
The move allows the Madhya Pradesh-based pharma and biotech company to secure capital for expansion while providing an exit for existing shareholders through a significant offer-for-sale.
The company established a price band with an upper bound of ₹988 per share [3]. Reports on the lower bound vary between ₹933 [2] and ₹938 [1] per share. Investors must bid for a minimum lot size of 15 shares, which costs ₹14,820 at the upper price band [7].
The total issue size of Rs 1,757 crore [4] consists of a fresh issue of Rs 150 crore [9] and an offer-for-sale of up to Rs 1,607 crore [10]. The company expects the issue to close on Aug. 27, 2026 [6].
According to the company's filings, the allotment of shares is expected on Aug. 28, 2026 [12], with the formal listing on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) scheduled for Sept. 1, 2026 [11].
At the upper price band, the post-issue market capitalization of the firm is estimated at Rs 6,348.5 crore [8]. This valuation represents 52 times the diluted earnings per share for the 2026 fiscal year [13].
“Symbiotec Pharmalab Ltd will open its Rs 1,757 crore initial public offering for subscription on Aug. 24, 2026.”
The heavy weighting toward an offer-for-sale suggests that the IPO is primarily a liquidity event for early investors rather than a primary capital raise for the company. However, the fresh issue of Rs 150 crore provides a targeted injection of cash for expansion. The valuation multiple of 52 times FY26 diluted EPS indicates high growth expectations from the company and its backers in the biotech sector.
